Shares of KemPharm Inc. (NASDAQ:KMPH) saw an uptick in trading volume on Tuesday . 125,626 shares were traded during mid-day trading, an increase of 61% from the previous session’s volume of 77,868 shares.The stock last traded at $4.80 and had previously closed at $4.31.

Several research firms recently commented on KMPH. Zacks Investment Research raised shares of KemPharm from a “hold” rating to a “buy” rating and set a $4.75 price objective on the stock in a research report on Tuesday. Canaccord Genuity reiterated a “buy” rating on shares of KemPharm in a research note on Wednesday, August 10th. Oppenheimer Holdings Inc. reiterated a “buy” rating and issued a $11.00 price target on shares of KemPharm in a research note on Tuesday, June 14th. Finally, Royal Bank Of Canada reiterated a “buy” rating on shares of KemPharm in a research note on Sunday, May 8th.

The firm’s market cap is $73.38 million. The stock’s 50 day moving average is $4.18 and its 200 day moving average is $10.21.

KemPharm (NASDAQ:KMPH) last posted its quarterly earnings data on Wednesday, August 10th. The specialty pharmaceutical company reported ($0.58) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.94) by $0.36. Equities research analysts anticipate that KemPharm Inc. will post ($2.44) earnings per share for the current fiscal year.

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.